HeitJA.Epidemiology of venous thromboembolism.Nat Rev Cardiol2015;
12: 464.
2.
GrosseSDNelsonRENyarkoKA, et al.
The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs.Thrombosis Res2016;
137: 3–10.
3.
RowswellHRNokesTJ.Significant reduction in hospital-acquired thrombosis: impact of national risk assessment and real-time feedback.Open Heart2017;
4: e000653.
4.
The National Institute for Health and Care Excellence. NICE guideline NG89, Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism 2018; I. Available at: https://www.nice.org.uk/guidance/ng89
5.
DeheinzelinDBragaAMartinsL, et al.
Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross‐sectional study in Brazil.J Thromb Haemostasis2006;
4: 1266–1270.
6.
LeonardiMJMcGoryMLKoCY.The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials.Arch Surg2006;
141: 790–799.
7.
EnglandN. The Official Statistics for Venous Thromboembolism (VTE) Risk Assessment in England for Quarter 3 2016/17. NHS, 2017.
8.
GreeneMTSpyropoulosACChopraV, et al.
Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med2016;
129: 1001. e9–e18.
9.
RosenbergDEichornAAlarconM, et al.
External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc2014;
3: e001152.
10.
BahlVHuHMHenkePK, et al.
A validation study of a retrospective venous thromboembolism risk scoring method.Ann Surg2010;
251: 344–350.
